Stève Consultants
French health consulting firm providing market access, HEOR, and real-world evidence services to pharmaceutical, biotechnology, and medical device companies seeking reimbursement and market entry in France. Operates as part of Cytel.
- Company typePrivate
- Founded2006
- HeadquartersOullins, France
- Headcount11–50
- GTM typeB2B
- OfferingServices
What Stève Consultants does
Stève Consultants is a France-based B2B consulting firm specializing in market access, health economics and outcomes research (HEOR), and real-world evidence (RWE) for health products. Founded approximately 2004-2005 and headquartered in Oullins (Lyon area) with a Paris office, the firm has accumulated nearly two decades of experience supporting pharmaceutical, biotechnology, and medical device companies in obtaining and maintaining reimbursement for medications, vaccines, in-vitro diagnostics, and digital health solutions in France. The company tracks 750+ dossiers submitted to the Haute Autorité de Santé (HAS), 50+ economic model developments, 20+ HEOR evaluations, and 150+ RWE studies.
The firm operates three integrated service pillars: Market Access (pricing and reimbursement strategy, early access programs, HTA interactions with HAS, EU Joint Clinical Assessment support), HEOR (economic model development, efficiency dossiers for CEESP, international model adaptation), and RWE (epidemiological and pharmaco-epidemiological studies using the SNDS database linked with clinical registries, primary data, and clinical trials). Its underlying technology leverages statistical and machine learning methods including propensity scores, matching algorithms, predictive models, random forest, clustering, and treatment sequence analysis to extract insights from French national health data.
Stève Consultants generates revenue through professional services engagements priced on a quote basis, with no publicly disclosed pricing or standardized rate cards. The go-to-market is expert-led, relying on direct B2B engagement, industry event presence (e.g., ISPOR), thought leadership content via the Cytel platform, and referrals. The company is now a wholly-owned subsidiary of Cytel, integrated into the global clinical research and analytics organization while maintaining its French offices and customer relationships.
Stève Consultants firmographics
Firmographics- Name
- Stève Consultants
- Legal name
- stève consultants
- Website
- https://steve-consultants.com
- Company type
- Private
- Founded year
- 2006
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- French health consulting firm providing market access, HEOR, and real-world evidence services to pharmaceutical, biotechnology, and medical device companies seeking reimbursement and market entry in France. Operates as part of Cytel.
- Ownership category
- akta.pro rank
Stève Consultants industry classification
Industry- Product category
- Pharmaceutical Market Access Consulting
- NAICS
- Management Consulting Services (54161)
- SIC
- Services-Management Consulting Services (8742)
- akta.pro primary industry
- Real-World Evidence (RWE), HEOR & Epidemiology CROs (HLAGAAAK)
- akta.pro secondary industries
- Health Economics & Outcomes Research (HEOR) (HLAIAKAB), Pricing & Contracting Strategy (HLAIAKAA), Real-World Evidence (RWE) & HEOR for Development (HLAIALAI), Market Access, Pricing & Reimbursement (Evidence Generation) FSP (HLAGAOAN)
Keywords
Where Stève Consultants is headquartered
LocationHeadquarters
- HQ city
- Oullins
- HQ country
- France
- HQ region
- Europe
Offices2 records
Markets served
Stève Consultants business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Operations, Technology or R&D, Marketing or Sales, Others
Revenue model
- Market Access Consulting: Strategic consulting services for pricing and reimbursement strategies in France, including dossier preparation for HAS, early access programs, and interactions with health authorities.
- HEOR Services: Health Economics and Outcomes Research services including efficiency dossiers for CEESP, economic model development, scientific communications, and international model adaptation to French context.
- Real-World Evidence Studies: Epidemiological and pharmaco-epidemiological studies using SNDS database for descriptive epidemiology, real-world effectiveness, clinical practices, and medico-economic analyses.
Go-to-market motion1 record
Distribution channels1 record
Marketing channels4 records
Stève Consultants product offering
Product offeringCore offering
Stève Consultants provides market access consulting, health economics and outcomes research (HEOR), and real-world evidence (RWE) studies for pharmaceutical, biotech, and medical device companies seeking reimbursement and market entry in France. Services include HAS dossier preparation, pricing and reimbursement strategy, economic model development, CEESP efficiency dossiers, epidemiological studies using the SNDS database, and EU Joint Clinical Assessment (EU-JCA) support.
Product overview
Stève Consultants, part of Cytel, is a French market access consultancy offering three integrated service pillars: Market Access (pricing/reimbursement strategy and HTA interactions), Health Economics and Outcomes Research (HEOR) including economic modeling and CEESP dossiers, and Real-World Evidence (RWE) studies using the SNDS database. The services are designed to work together to support health product reimbursement in France, with capabilities for both local French projects and international multi-country studies.
Differentiator
Problem solved
Functional benefit
Products and services
- Market Access Services Strategic consulting for local pricing and reimbursement strategies, early access programs for innovative medications, and HTA interactions with French health authorities (HAS) including dossier preparation and committee meetings. Targeted at pharmaceutical, biotech, and medical device manufacturers seeking market entry and reimbursement in France.
- Health Economics and Outcomes Research (HEOR) Development and adaptation of economic models, efficiency dossiers for French authorities (CEESP), scientific communications, and international model adaptation to the French context to support pricing and reimbursement positioning.
- Real-World Evidence (RWE) Epidemiological and pharmaco-epidemiological studies using the French SNDS database (DCIR, ESND, PMSI) combined with clinical data sources, supporting market access strategy through data on patient characteristics, treatment patterns, and healthcare consumption.
- EU Joint Clinical Assessment (EU-JCA) Support Local contributions aligned with payer requirements for international market access strategy, with collaboration across European teams to support EU-JCA preparation for health products entering European markets.
Quantifiable outcome
- 750+ dossiers submitted to HAS across medications, biotech, and medical devices
- +3 more outcomes
Companies that use Stève Consultants
Customer profileSegments4 records
Ideal customer profiles3 records
Stève Consultants technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability3 records
Feature3 records
Stève Consultants partnerships and signals
Strategic signalPartnerships
One partnership is on record.
- CytelcoreStève Consultants was acquired and integrated into Cytel, becoming part of Cytel's global network of strategic consulting services. This integration combines Stève's local French market expertise with Cytel's international reach, enabling clients to access both local market knowledge and global clinical trial and analytics capabilities.
Scale indicators5 records
Recent moves5 records
Expansion highlights4 records
Stève Consultants competitors and assessment
Company assessmentBroad incumbents
- Evidera: Large multi-country HEOR, RWE, and market access consultancy (now part of Thermo Fisher/PPRD) offering broader service portfolio than Stève. Broader incumbent competing for the same pharma/biotech HEOR and RWE mandates.
- Parexel (Market Access Consulting): Global CRO with a market access and HEOR consulting arm serving pharma and biotech. Broader-scope incumbent that overlaps with Stève on HEOR models, RWE, and HTA dossier work.
- IQVIA Real World Solutions: Global CRO and healthcare data giant with a dedicated Real World Solutions practice delivering HEOR, market access, and large-scale RWE. Broad incumbent whose France team competes head-to-head with Stève.
Direct peers
- RTI Health Solutions: US-based RWE/HEOR research organization serving pharma, biotech, and medical device clients globally with health economics, real-world data, and market access services. Direct competitor on RWE generation and HEOR modeling for global pharma accounts.
- LASER Analytica: European HEOR, market access, and RWE consultancy headquartered in France. Comparable to Stève via shared SNDS exploitation, HAS dossier services, and pharma/biotech client base across therapeutic areas.
- CEMKA Eval: French HEOR, market access, and pharmaco-epidemiology consultancy serving pharma, medtech, and public health stakeholders. Highly comparable to Stève as a French-headquartered competitor with overlapping dossiers, HAS submissions, and SNDS/RWE expertise.
- Creativ-Ceutical: Global HEOR, market access, and RWE consultancy founded in Paris, providing health economics modeling, HTA submissions, and real-world studies across Europe. Direct competitor to Stève in French market access and economic dossier delivery.
- NEXTEP: French consultancy advising life sciences clients on market access, HEOR, and health technology assessment. Closely comparable niche operator targeting pharma, biotech, and medtech with reimbursement support in France.
- Amaris Consulting (Market Access & HEOR): International consultancy with a France-based life sciences practice providing market access and HEOR services to pharma and medical device companies. Overlaps with Stève on French market access strategy and economic evaluations.
Emerging players
- Maple Health Group: Specialized HEOR and market access consultancy with growing European footprint. Comparable positioning to Stève in providing economic models and HTA support, though smaller and more recent in the French market.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat4 records
Key risks6 records
Key highlights6 records
Customer concentration
Stève Consultants social profiles
Digital presenceStève Consultants financial estimates
Financial estimateRevenue estimate
Valuation estimate
Stève Consultants leadership team
Management profileNumber of profiles
Profiles5 records
Stève Consultants funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Stève Consultants M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Stève Consultants
What does Stève Consultants do?
Stève Consultants provides market access consulting, health economics and outcomes research (HEOR), and real-world evidence (RWE) studies for pharmaceutical, biotech, and medical device companies seeking reimbursement and market entry in France. Services include HAS dossier preparation, pricing and reimbursement strategy, economic model development, CEESP efficiency dossiers, epidemiological studies using the SNDS database, and EU Joint Clinical Assessment (EU-JCA) support.
Is Stève Consultants a public or private company?
Stève Consultants is a private company. It is classified as corporate owned and is currently operating.
When was Stève Consultants founded?
Stève Consultants was founded in 2006. It employs 11 to 50 people.
Where is Stève Consultants based?
Stève Consultants is headquartered in Oullins, France, in the Europe region.
How does Stève Consultants make money?
Three revenue lines are on record. Market Access Consulting is the primary driver. The others are HEOR Services and real-World Evidence Studies.
Who are Stève Consultants's main competitors?
Broad incumbents on record are Evidera, Parexel (Market Access Consulting) and IQVIA Real World Solutions. Direct peers are RTI Health Solutions, LASER Analytica, CEMKA Eval, Creativ-Ceutical, NEXTEP and Amaris Consulting (Market Access & HEOR). Maple Health Group is listed as an emerging player.
Does Stève Consultants have an API?
No public API is recorded for Stève Consultants.
What industry is Stève Consultants in?
Stève Consultants's product category is Pharmaceutical Market Access Consulting. Its primary akta.pro industry code is HLAGAAAK, Real-World Evidence (RWE), HEOR & Epidemiology CROs, with a secondary code of HLAIAKAB, Health Economics & Outcomes Research (HEOR). Its NAICS code is 54161 and its SIC code is 8742.